Addex Spin-Out Neurosterix Publishes Preclinical Data for Anxiety Treatment
Summary
Addex Therapeutics announced the publication of preclinical data in Molecular Psychiatry, supporting the potential of mGlu7 Negative Allosteric Modulators (NAMs) from its spin-out, Neurosterix, to treat anxiety and fear-related disorders.
Key Events
-
Preclinical Data Publication
Addex announced the publication of preclinical data in Molecular Psychiatry for ADX71743, an mGlu7 Negative Allosteric Modulator (NAM).
-
Potential for Anxiety & Fear Disorders
The data supports the potential of mGlu7 NAMs to transform treatment for anxiety and fear-related disorders, including PTSD, by disrupting fear memory reconsolidation.
-
Neurosterix Asset Validation
ADX71743 and other mGlu7 NAMs are part of the portfolio of Neurosterix LLC, Addex's spin-out in which Addex holds a 20% equity interest, validating a key strategic investment.
Analysis
This filing highlights positive preclinical data for ADX71743, an mGlu7 NAM, demonstrating its potential to disrupt fear memory reconsolidation. The data, published in a peer-reviewed journal, provides scientific validation for a differentiated mechanism to treat anxiety and fear-related disorders like PTSD. While ADX71743 is part of the Neurosterix pipeline (in which Addex holds a 20% equity interest), this publication reinforces the scientific foundation of the spin-out's assets and Addex's strategic investment. This follows the recent announcement on January 7, 2026, of Neurosterix commencing a Phase 1 study for another mGlu7 NAM, NTX-253, further building momentum for the platform.
At the time of this filing, ADXN was trading at $7.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $6.51 to $12.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.